The Corporate and Foundations Relations Office is able to work with faculty applying for corporate and foundation opportunities below. Please contact them by email or by phone at 919.962.2867. For all applications, please be sure to work with your Department of Pediatrics division grants administrator. Headlines are linked for more information.
Information about funding opportunities related to the novel coronavirus (COVID-19) will be added to the UNC Office of Research website as they become available. These include opportunities from the National Institutes of Health, the National Science Foundation and the Centers for Disease Control and Prevention.
Alex’s Lemonade Stand Foundation (ALSF) is accepting applications to support a new generation of translational and clinical researchers interested in tackling inherited hematologic malignancy predisposition disorders with a focus on RUNX1-familial platelet disorder. Applicants must have research experience working in, and a deep understanding of, normal or malignant hematopoiesis and/or immunology. Proposals that seek to translate from bench to bedside will receive priority. The application deadline is December 16, 2020.
The American Heart Association, in partnership with Enduring Hearts, is accepting Letters of Intent to support investigators who are actively conducting research directly related to improving the life expectancy and quality of life of Pediatric Heart Transplant Recipients. This funding opportunity will further these areas of focus by offering competitive research grants in basic, clinical, population, and/or translational research via Collaborative Sciences Awards. The letter of intent deadline is October 1, 2020; invited full proposals due January 15, 2021.
The Angelman Syndrome Foundation (ASF) is accepting proposals to fund pilot projects to test new ideas about pathogenesis and therapeutics of Angelman syndrome, translational research and clinical research studies. Deadlines – October 15 and April 15.
As part of the mission of the Children’s Research Institute (CRI) to coordinate and support pediatric research, we are thrilled to announce 3 research funding opportunities: 1) Carolina For the Kids (CFTK) Research Grant Awards; 2) UNC Children’s Development Early Career Investigator Grants; and 3) IQVIA Pediatric Clinical Scholars Award.
The deadline for the CFTK Research Grant Awards and the UNC Children’s Development Early Career Investigator Grants is midnight on Monday, October 5, 2020. The IQVIA Scholar Award is not accepting applications for the 2020 cycle.
The Damon Runyon Cancer Research Foundation is accepting applications to support from physicians interested in pursuing research intensively for up to four years, while, if they wish to maintain their clinical skills, continue to be clinically active. To be eligible, applicants must have MDs or DOs only and must have completed their residencies and clinical training and be US Specialty Board eligible prior to the award start date. The application deadline is December 1, 2020.
The Damon Runyon Cancer Research Foundation is accepting applications to support quantitative scientists (trained in fields such as mathematics, computer science, physics, engineering, or related) to pursue research careers in computational biology under the joint mentorship of leaders in both computational science (“dry lab”) and cancer biology (“wet lab”). By investing in this area, Damon Runyon will bring additional attention to the importance of these specially trained scientists for making meaningful progress in cancer biology. The application deadline is December 1, 2020.
The purpose of the Doris Duke Clinical Scientist Development Award is to provide support to physician scientists at the Instructor or Assistant Professor rank to: 1) conduct an outstanding clinical research project with high significance to improve human health, 2) enable research time protection to ease the tension between research and clinical responsibilities, and 3) facilitate development of strong mentorship relations in a supportive institutional environment. The Foundation does not have funding priorities based on disease area or research type; however, experiments that use animals or tissues derived from animals, including cell lines, will not be supported by this program. Pre-proposal applications are being accepted until November 13, 2020 at 3 p.m. ET. Invitations to submit full applications will be sent by January 15, 2021.
This Funding Opportunity Announcement invites grant applications that address priority gaps in understanding the role of nutrition in the care and development of preterm infants. Applications are due November 30, 2020.
This FOA invites applications to form the Knowledge and Research Coordination Center of the NICHD’s Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct therapeutics-focused research in obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities. Applications are due November 30, 2020.
The Gerber Foundation is accepting concept papers for proposals that focus on pediatric health or pediatric nutrition research. Projects focusing on pediatric nutrition focus on applied research that evaluates the provision of specific nutrients and their related outcomes in infants and young children. Applied research projects under pediatric health are focused on reducing the incidence of serious neonatal and early childhood illnesses, improving cognitive, social and emotional aspects of development. Projects should have wide-spread implications for health or nutrition and should be able to have impact within three years of study. The concept paper deadline is November 15, 2020; invited full proposals due February 15, 2021.
A Kids’ Brain Tumor Cure (AKBTC), also known as the Pediatric Low Grade Astrocytoma Foundation, Inc., is accepting Letters of Intent (LOIs) to support researchers and provides funds that will act as a catalyst to help the researchers turn their attention to the area of pediatric low grade glioma brain tumor research. $100,000 – $500,000, depending on project scope and duration. The grant cycle is an ongoing process throughout the year.
The NIH Director’s Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications are welcome in all topics relevant to the broad mission of NIH, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. Applications are due September 30, 2020.
The National Cancer Institute invites applications describing research focused on improving care and health-related quality of life for childhood, and adolescent and young adult (AYA) cancer survivors. NCI intends to commit $50 million total across FY22 to fund up to 14 awards. The maximum project period is 5 years. The application deadline is July 30, 2021.
The North Carolina Translational and Clinical Sciences Institute (NCTraCS) provides a variety of pilot funding opportunities to facilitate the transfer of research findings to clinical practice in order to improve the health of the people of North Carolina. Multiple grant mechanisms are available.
This PCORI funding announcement invites applications for high-quality comparative effectiveness research projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs. The proposed trials should address important decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions. Proposed studies should compare interventions that already have established evidence of efficacy or are in widespread use. Clinical interventions (such as medications, diagnostic tests, or procedures) and delivery system interventions are appropriate for study. Letter of intent is due September 29, 2020 at 5:00 pm; full applications are due January 21, 2021 at 5:00 pm.
Pfizer’s Global Medical Grants program is accepting applications to support education programs for dermatologists and allergists on new small molecule and biological based emerging therapies of moderate-to-severe atopic dermatitis, as well as the emerging mechanisms of action in the treatment of this disease. Pfizer does not intend to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. The intended audience for this funding program is dermatologists and allergists involved in the care and treatment of patients with moderate-to-severe atopic dermatitis. Applications are due October 15, 2020.
Pfizer’s Global Medical Grants program is accepting applications to support projects that will focus on Healthcare Practitioners (HCPs) that may encounter and/or diagnose, refer, or treat patients with pJIA. Educating the HCP community on pJIA will help to potentially reduce time in accurately identifying and diagnosing pediatric patients, which will improve patient outcomes. It is not the intent of this award to support clinical research projects. Projects evaluating
the efficacy of therapeutic or diagnostic agents will not be considered. Applications are due on October 23, 2020.
The PROMISE study is currently recruiting underrepresented postdocs for peer mentoring and professional development activities as part of the study and will extend to junior faculty in the Spring. You may qualify to participate if you identify as Black or African American, Hispanic or Latinx, American Indian or Alaskan Native, Native Indian or other Pacific Islander, and/or Multiracial and are involved in biomedical research. You must be a U.S. citizen or permanent resident to participate. Please see attached flyer for more information.
The Office of Research is inviting applications from faculty for Boost awards, which are designed to boost the chances of funding for an NIH grant (or similar) that has been reviewed favorably but needs additional revisions and preliminary data in order to be funded on resubmission. Please note that Boost awards are distinct from the Office of Research’s Bridge Funding program, which provides funds for bridging A1 renewal applications for ongoing, not new, projects. The deadline for application is 5 P.M. Friday, October 2, 2020.
The School of Medicine is opening the first round of applications for Bridge Funding for this fiscal year. Bridge Funding provides continued support for successful research projects that suffer a lapse in funding. Investigators eligible for funding in this round should have had a competing renewal application for an R01 or equivalent grant reviewed in the most recent review cycle (June/July 2020). The deadline for submission of applications is 5 P.M. Friday, October 2, 2020.
The Melanoma Research Alliance is pleased to partner with St. Baldrick’s Foundation to offer a special opportunity to support research to improve the diagnosis, understanding, and treatment of pediatric melanoma. Early career faculty are encouraged to submit research proposals addressing the following Special Emphasis Areas: 1) Identifying novel techniques and biomarkers to aid in accurate diagnosis and optimize management of pediatric/adolescent patients; 2) Elucidating the underlying mechanisms of melanoma development in pediatrics; 3) Understanding clinical differences in presentation between pediatric and adult melanoma; 4) Collecting real-world data on pediatric melanoma to inform the biological basis for melanoma formation in children versus adults; and 5) Analyzing similarities and differences between melanoma in children/adolescents and in adults relevant to immunogenicity and potential impact of immunotherapies. Applicants should submit to the general Young Investigator Award program and designate their desire to be considered for this award when completing their online application. The Young Investigator Eligibility Checklist is due by October 21, 2020; full applications are due by November 4, 2020.
The Thrasher Research Fund is accepting Concept Papers to support young investigators in pediatric research. The program’s aim is to encourage the development of medical research in child health by awarding small grants to new researchers. The grant cycle is an ongoing process throughout the year.